Health Care; Pharmaceutical; Diagnostic; Medical Device; Manufacturing; Biotech; Consumer Products; Chemical; Biopharmaceutical; Financial Services; Technology
Abbott; Akron Molecules; Alkem Laboratories; Astellas; AstraZeneca; Baxter; Baxter Healthcare; Bayer; Becton Dickinson; Biogen Idec; BMS; Bracco Diagnostics; Covidien; Cubist Pharmaceuticals; Eisai; Endo Health Solutions; Esteve; Ethicon; Ferring Pharmaceuticals; Forest; Genentech; Gilead; GlaxoSmithKline; Grunenthal; Guerbet; Ipsen; LifeCell; Janssen; MAP Pharmaceuticals; MedImmune; Medtronic; Methapharm; MSD Pharma; Mylan; Novartis; Novo Nordisk; Onyx; Pfizer; Philips Healthcare; Ranbaxy; Roche; Sanofi Pasteur; Shire; Shire HGT; Teva; UCB; Upsher-Smith Labs; Valeant; ViroPharma; Xanodyne
The report is based on the insights of 68 Medical Affairs executives and managers at 50 leading global companies. The benchmark class in this study consists of a Mature Markets and Emerging Markets Segment. The Mature Market Segment includes 41 participants from pharma and 12 device respondents. The Emerging Markets Segment consists of 15 participants working in India, China, Brazil, and Turkey.
Key research objects include:
- Illustrate how leading Pharmaceutical and Medical Device companies structure and organize their Medical Affairs functions based on industry and market changes.
- Identify trends expected to impact the allocation of resources across different Medical Affairs functions.
- Analyze how regulatory requirements are internalized and managed by Medical Affairs.
- Describe the success factors and top current challenges regarding Medical Affairs.
- Identify what percentage of MA budget leading companies allocate for outsourcing spending.
- Trace how successful Medical Affairs organizations work cross-functionally to enhance effectiveness.